Organizational Chart International Technology Transfer General Information Career Opportunities


Spacer

 
Neglected Diseases


Technologies Available for Licensing from NIH/FDA


Buruli ulcer

No NIH/FDA Technology Abstracts are available for this Neglected Disease/Condition at this time.

Cholera

Development of a Plant Derived Recombinant Subunit Vaccine Candidate Against Hepatitis C
Hepatitis C virus (HCV) is a major cause of acute and chronic hepatitis with over 180 million cases worldwide. Development of a vaccine to combat HCV has been difficult. Presently, the virus cannot be grown in tissue culture and there is no vaccine or effective therapy against this virus. This technology relates to the development of an experimental plant-derived subunit vaccine against HCV. A tobamoviral vector was engineered to encode a con...  More ...

Vibrio cholerae O139 Conjugate Vaccines
Cholera remains an important public health problem. Epidemic cholera is caused by two Vibrio cholerae serotypes O1 and O139. The disease is spread through contaminated water. According to information reported to the World Health Organization in 1999, nearly 8,500 people died and another 223,000 were sickened with cholera worldwide. This invention is a polysaccharide-protein conjugate vaccine to prevent and treat infection by Vibrio cholerae O...  More ...


Leprosy

Novel Anti-Mycobacterial Compositions and Their Use for the Treatment of Tuberculosis and Related Diseases
This invention comprises a number of novel anti-mycobacterial compositions, which offer to significantly improve the treatment of mycobacterial infection such as tuberculosis. Mycobacterium is a genus of bacteria encompassing a number of organisms, many of which are highly pathogenic in humans. The most well known of these are M. tuberculosis, which causes pulmonary tuberculosis, and M. leprae, which causes leprosy. Tuberculo...  More ...


Trachoma

No NIH/FDA Technology Abstracts are available for this Neglected Disease/Condition at this time.

Tuberculosis

Alleviating Symptoms of Th2-Like Cytokine Mediated Disorders by Reducing IL-13 Receptor-Expressing Cells in the Respiratory Tract
This invention relates to the alleviation of symptoms of Th2-like cytokine mediated disorders, such as allergy, asthma, and to hyperinflammatory responses in the respiratory tract to infectious diseases and parasitic infections, including tuberculosis, schistosomiasis, leishmania, and filariasis.

This invention claims a variety of methods and uses of a chimeric molecule comprising a toxic moiety and a targeting moiety that specificall...  More ...


Novel Attenuated Strains of Mycobacterium Tuberculosis
This invention provides for novel attenuated strains of Mycobacterium tuberculosis and M. bovis. Attenuation is achieved by deleting the gene encoding the alpha-crystallin heat shock protein ("acr gene"). This gene contributes to the virulence of the organism. Since this strain is isogenic with virulent M. tuberculosis but for this deletion, the full complement of antigens remains present and the organism is viable in v...  More ...

Novel Anti-Mycobacterial Compositions and Their Use for the Treatment of Tuberculosis and Related Diseases
This invention comprises a number of novel anti-mycobacterial compositions, which offer to significantly improve the treatment of mycobacterial infection such as tuberculosis. Mycobacterium is a genus of bacteria encompassing a number of organisms, many of which are highly pathogenic in humans. The most well known of these are M. tuberculosis, which causes pulmonary tuberculosis, and M. leprae, which causes leprosy. Tuberculo...  More ...

Aerosolized Capreomycin for Inhibition of Pulmonary Tuberculosis
This technology involves the methods of reformulation of Capreomycin for the aerosol treatment of pulmonary tuberculosis.

Tuberculosis is a devastating lung disease that is highly infectious and easily transmitted, especially in areas of overcrowding such as prisons. Furthermore, underdeveloped countries with large populations living in close quarters maintain an endemic disease reservoir limiting the health and economic viability of...  More ...


Method of Diagnosing Multidrug Resistant Tuberculosis
The invention relates to the discovery that a putative gene of Mycobacterium tuberculosis (MTb) with no previously identified function is responsible for the ability of the bacteria to activate a class of second line thioamide drugs used for MTb infections. The gene, termed "etaA", codes for the synthesis of a monooxigenase, the enzyme responsible for the oxidative activation of the drugs. Mutation in the etaA gene leads to the expression ...  More ...

Mouse Fibroblasts Stably Expressing C-Type Lectin Receptors DC-SIGN and L-SIGN
The NIH is pleased to offer for licensing mouse fibroblasts that stably express the C-type lectin receptors DC-SIGN and L-SIGN (CD209 and CD209L, respectively). L-SIGN and DC-SIGN both exhibit selectivity for highly mannosylated glycoproteins. DC-SIGN is also selective for certain Lewis X sugar groups. These types of interactions allow L-SIGN and DC-SIGN to interact with a wide spectrum of pathogens including HIV, hepatitis C virus, and SARS c...  More ...


Yaws

No NIH/FDA Technology Abstracts are available for this Neglected Disease/Condition at this time.


Technologies Available for Licensing from Non-Profit Institutions


Buruli ulcer
Massachusetts General Hospital

Photosensitizer Conjugates For Targeting Intracellular Pathogens

Cholera
Massachusetts General Hospital

Strain Typing Of E. Coli O157:h7
Massachusetts General Hospital

Compositions Comprising Grim-19 And Methods Of Use Thereof For The Treatment Of Intracellular Pathogens
Massachusetts General Hospital

Use Of The Rtx Secretion System To Achieve Heterologous Antigen Secretion In Vibrio Cholera

Leprosy
Dana-Farber Cancer Institute

Inhibitors Of P. Carinii: Dihydrofolate Reductase With Marked Improved In Potency Relative To Trimethoprim And Species Selectivity Relative To Piritrexim
Massachusetts General Hospital

Photosensitizer Conjugates For Targeting Intracellular Pathogens

Trachoma
University of Massachusetts at Amherst

Quanitification Of Chlamydia Infection Through Flow Cytometry And Anti-chlamydial Glycolipid Exoantigen (glxa) Antibody

Tuberculosis
Harvard University

Susceptibility To Tuberculosis 1 (sst1): Novel Target For Diagnosis And Treatment Of Mycobacterium Tuberculosis
Harvard University

Novel Candidates For Tuberculosis Therapy
Boston Biomedical Research Institute

Methods And Compositions For Specific Inhibition Of Protein Splicing By Small Molecules For The Treatment Of Turberculosis
Brigham and Women's Hospital

Activation Of T Cells By Cd1a And Lipopeptide Antigens
Brigham and Women's Hospital

T Cell Activation By Cd1d And Sulfated Polyaromatic Hydrocarbons
Massachusetts General Hospital

Photosensitizer Conjugates For Targeting Intracellular Pathogens


Bacterial Infections Helminthic Infections Protozoan Infections
Viral Infections
 
Bullet Overview
Bullet Buruli ulcer
Bullet Cholera
Bullet Leprosy
Bullet Trachoma
Bullet Tuberculosis
Bullet Yaws
 
 
Spacer